GlassScriptPhysician profile
Mark M Byarlay
NPI 1164483830
$11,754.10
in general payments reported to CMS, 2019-2025
56 companies · $1,499 in 2025
The $1,499 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,696 · 2020: $1,732 · 2021: $1,838 · 2022: $1,665 · 2023: $1,606 · 2024: $1,719 · 2025: $1,499.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,824.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,823.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,425.67 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $1,296.46 | 2019-2025 | Ubrelvy, Linzess, Qulipta |
| Novo Nordisk INC | $1,174.72 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $860.55 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $843.26 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $700.09 | 2019-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $610.66 | 2019-2024 | Trintellix |
| Pfizer INC. | $407.60 | 2020-2025 | |
| Amgen INC. | $349.57 | 2019-2025 | Repatha, Repatha, Otezla |
| Amarin Pharma, INC. | $310.87 | 2019-2021 | |
| Abbott Laboratories | $244.90 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Daiichi Sankyo INC. | $241.10 | 2019-2023 | Injectafer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $204.35 | 2019-2025 | Xifaxan |
| Allergan, INC. | $198.39 | 2019-2020 | |
| Eisai INC. | $197.95 | 2019-2021 |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Byarlay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.